<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738879</url>
  </required_header>
  <id_info>
    <org_study_id>0431-845</org_study_id>
    <secondary_id>2015-004990-34</secondary_id>
    <secondary_id>MK-0431-845</secondary_id>
    <nct_id>NCT02738879</nct_id>
  </id_info>
  <brief_title>Randomized Sitagliptin Withdrawal Study (MK-0431-845)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants
      with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and
      titrate insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting
      glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that
      after 30 weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C
      (A1C) relative to withdrawing sitagliptin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in A1C at Week 30</measure>
    <time_frame>Baseline and Week 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Rate of Documented Symptomatic Hypoglycemia with Blood Glucose (BG) ≤70 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to 32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Documented Symptomatic Hypoglycemia with BG ≤70 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Documented Symptomatic Hypoglycemia with BG ≤56 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Documented Hypoglycemia with BG ≤70 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Documented Symptomatic Hypoglycemia with BG ≤56 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 30 in Total Daily Insulin Dose</measure>
    <time_frame>Baseline and Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with A1C goal &lt;7.0% (&lt;53 mmol/mol) at Week 30</measure>
    <time_frame>Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with A1C goal &lt;7.0% (&lt;53 mmol/mol) at Week 30 With No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) During the 30-week Treatment Period</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 30 in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline and Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Documented Hypoglycemia with BG ≤56 mg/dL</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg, oral, once daily for 30 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg, oral, once daily for 30 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to stiagliptin</intervention_name>
    <description>Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LANTUS®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have T2DM based on American Diabetes Association guidelines

          -  Be on one of the following treatment regimens:

               1. Stable dose of sitagliptin (100 mg/day) and metformin IR or XR (metformin)
                  (≥1500 mg/day) either co-administered or as a fixed dose combination (FDC) for
                  ≥12 weeks with A1C between 7.5% and 11.0%, inclusive.

                  OR

               2. Stable dose of metformin (≥1500 mg/day) and another dipeptidyl peptidase-4
                  (DPP-4) inhibitor (at maximum labeled dose, other than sitagliptin, either
                  co-administered or as a FDC, for ≥12 weeks with A1C between 7.5% and 11.0%,
                  inclusive.

                  OR

               3. Stable dose of sitagliptin (100 mg/day) and metformin (≥1500 mg/day) either
                  co-administered or as a FDC, and a sulfonylurea for ≥12 weeks OR stable dose of
                  metformin (≥1500 mg/day) and a sulfonylurea administered as a FDC and
                  sitagliptin (100 mg/day) with A1C between 7.0% and 10.0%, inclusive.

                  OR

               4. Stable dose of metformin (≥1500 mg/day) and another DPP-4 inhibitor (at maximum
                  labeled dose), other than sitagliptin, either co-administered or as a FDC, and a
                  sulfonylurea for ≥12 weeks OR stable dose of metformin (≥1500 mg/day) and a
                  sulfonylurea administered as a FDC and another DPP-4 inhibitor other than
                  sitagliptin with A1C between 7.0% and 10.0%, inclusive OR

               5. Stable dose of metformin (≥1500 mg/day) and a sulfonylurea either
                  co-administered or as a FDC for ≥12 weeks with A1C between 7.5% and 11.0%,
                  inclusive.

          -  Meet one of the following categories:

               1. The participant is a male

               2. The participant is a female who is not of reproductive potential

               3. The participant is a female who is of reproductive potential and agrees to avoid
                  becoming pregnant while receiving study drug and for 14 days after the last dose
                  of study drug by practicing abstinence from heterosexual activity OR use (or
                  have her partner use) acceptable contraception during heterosexual activity

        Exclusion Criteria:

          -  Has been treated with any anti-hyperglycemic agent (AHA) other than
             protocol-specified agents (i.e., other than metformin, DPP-4 inhibitor, or
             sulfonylurea agent) within the prior 12 weeks.

          -  Has a history of 2 or more episodes of hypoglycemia resulting in seizure, coma, or
             loss of consciousness, OR has had recurrent (≥3 times per week) episodes of
             hypoglycemia over the past 8 weeks.

          -  Has a history of type 1 diabetes mellitus (T1DM) or ketoacidosis, or has a history of
             latent autoimmune diabetes of adults (LADA), is assessed by the investigator as
             possibly having T1DM or LADA confirmed with a C-peptide &lt;0.7 ng/mL (&lt;0.23 nmol/L), or
             has a history of other specific types of diabetes (e.g., genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, or
             post-organ transplant).

          -  Is assessed by the investigator to be not appropriate for, or does not agree to
             target, a fasting glucose of 72-100 mg/dL (4.0-5.6 mmol/L).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2329)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2321)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2303)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2318)</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2317)</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2315)</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2310)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2331)</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2304)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2330)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2337)</name>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2340)</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2324)</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2342)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2336)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2332)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2306)</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2311)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2343)</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2316)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2319)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2325)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2302)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2327)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2308)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2300)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2314)</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2312)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2305)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2326)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 2328)</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (Argentina) Inc.</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Wilkinson</last_name>
      <phone>54 11 4796 8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD SRO Czechýýýýýýýýýýýýýýý</name>
      <address>
        <city>Prague</city>
        <zip>Prague 6</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>420 233 010 111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Lassota</last_name>
      <phone>45 44824475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Blazy</last_name>
      <phone>33 147548990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barý</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gally Teper</last_name>
      <phone>972-9-9533310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongho Ahn</last_name>
      <phone>82-2-331-2000 2015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Marques</last_name>
      <phone>52 55254819608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (New Zealand) Ltd.,</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corporation</name>
      <address>
        <city>Makati</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Recto</last_name>
      <phone>632 784 9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>48 22ý478 43 24</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1705)</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1700)</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1704)</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1703)</name>
      <address>
        <city>San Juan</city>
        <zip>00909-3004</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1701)</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olaru</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Serebriakova</last_name>
      <phone>74959167100, EXT.366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Mateos Chacon</last_name>
      <phone>(0034) 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alev Eren</last_name>
      <phone>90 212 336 12 63</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Toms</last_name>
      <phone>+44 (0) 1992 452475</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>April 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
